2025-02-01 2026-01-31 false Capium Accounts Production 1.1 11161549 2025-02-01 2026-01-31 11161549 bus:FullAccounts 2025-02-01 2026-01-31 11161549 bus:FRS102 2025-02-01 2026-01-31 11161549 bus:AuditExemptWithAccountantsReport 2025-02-01 2026-01-31 11161549 bus:SmallCompaniesRegimeForAccounts 2025-02-01 2026-01-31 11161549 bus:PrivateLimitedCompanyLtd 2025-02-01 2026-01-31 11161549 2025-02-01 2026-01-31 11161549 2026-01-31 11161549 bus:RegisteredOffice 2025-02-01 2026-01-31 11161549 core:WithinOneYear 2026-01-31 11161549 core:AfterOneYear 2026-01-31 11161549 1 2025-02-01 2026-01-31 11161549 bus:Director1 2025-02-01 2026-01-31 11161549 bus:Director1 2026-01-31 11161549 bus:Director1 2024-02-01 2025-01-31 11161549 2024-02-01 11161549 bus:LeadAgentIfApplicable 2025-02-01 2026-01-31 11161549 2024-02-01 2025-01-31 11161549 2025-01-31 11161549 core:WithinOneYear 2025-01-31 11161549 core:AfterOneYear 2025-01-31 11161549 bus:EntityAccountantsOrAuditors 2024-02-01 2025-01-31 11161549 bus:OrdinaryShareClass1 2025-02-01 2026-01-31 11161549 bus:OrdinaryShareClass1 2026-01-31 11161549 bus:OrdinaryShareClass1 2024-02-01 2025-01-31 11161549 bus:OrdinaryShareClass1 2025-01-31 11161549 core:FurnitureFittings 2025-02-01 2026-01-31 11161549 core:FurnitureFittings 2026-01-31 11161549 core:FurnitureFittings 2025-01-31 11161549 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2026-01-31 11161549 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2025-01-31 11161549 core:CostValuation core:Non-currentFinancialInstruments 2026-01-31 11161549 core:CostValuation core:Non-currentFinancialInstruments 2025-01-31 11161549 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2026-01-31 11161549 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2026-01-31 11161549 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2026-01-31 11161549 core:Non-currentFinancialInstruments 2026-01-31 11161549 core:Non-currentFinancialInstruments 2025-01-31 11161549 core:ShareCapital 2026-01-31 11161549 core:ShareCapital 2025-01-31 11161549 core:RetainedEarningsAccumulatedLosses 2026-01-31 11161549 core:RetainedEarningsAccumulatedLosses 2025-01-31 11161549 core:ShareCapitalOrdinaryShares 2025-02-01 11161549 core:ShareCapitalOrdinaryShares 2024-02-01 11161549 core:ShareCapitalOrdinaryShares 2025-02-01 2026-01-31 11161549 core:ShareCapitalOrdinaryShares 2024-02-01 2025-01-31 11161549 core:ShareCapitalOrdinaryShares 2026-01-31 11161549 core:ShareCapitalOrdinaryShares 2025-01-31 11161549 core:RetainedEarningsAccumulatedLosses 2025-02-01 11161549 core:RetainedEarningsAccumulatedLosses 2024-02-01 11161549 core:RetainedEarningsAccumulatedLosses 2025-02-01 2026-01-31 11161549 core:RetainedEarningsAccumulatedLosses 2024-02-01 2025-01-31 11161549 core:RetainedEarningsAccumulatedLosses 2026-01-31 11161549 core:RetainedEarningsAccumulatedLosses 2025-01-31 11161549 dpl:Item1 2025-02-01 11161549 dpl:Item1 2026-01-31 11161549 dpl:Item1 2024-02-01 11161549 dpl:Item1 2025-01-31 iso4217:GBP xbrli:shares xbrli:pure
Logo On Report
Registered Number: 11161549
England and Wales

 

 

 

HEALTH FUSION CLINIC LIMITED


Unaudited Financial Statements
 


Period of accounts

Start date: 01 February 2025

End date: 31 January 2026
Director Ilan SLAZENGER,
Registered Number 11161549
Registered Office 70 Clapton Square
London
E5 8HW
Accountants Julius and Julius and Associates LLP
70 Clapton Square
London
E5 8HW
1
Director's report and financial statements
The director presents his/her/their annual report and the financial statements for the year ended 31 January 2026
Principal activities
The companys principal activity during the year was
86900 - Other human health activities
Director
The director who served the company throughout the year was as follows:
Ilan SLAZENGER,
Statement of director's responsibilities
The director is responsible for preparing the directors’ report and the financial statements in accordance with applicable law and regulation.

Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the director must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the director is required to
  • select suitable accounting policies and then apply them consistently
  • make judgments and accounting estimates that are reasonable and prudent
  • prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business


The director is responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. The director is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The director is responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

On behalf of the board.


----------------------------------
Ilan SLAZENGER,
Director

Date approved: 31 October 2026
2
Report to the directors on the preparation of the unaudited statutory accounts of HEALTH FUSION CLINIC LIMITED for the year ended 31 January 2026
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of HEALTH FUSION CLINIC LIMITED for the year ended 31 January 2026 which comprise of the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the company’s accounting records and from information and explanations you have given to us.

As a practising member firm of the Institute of Financial Accountants (IFA), we are subject to its ethical and other professional requirements which are detailed at https://www.ifa.org.uk/about-us/acting-in-the-public-interest/memberregulations.

This report is made solely to the Board of Directors of HEALTH FUSION CLINIC LIMITED, as a body, in accordance with the terms of our engagement letter dated 31 October 2026. Our work has been undertaken solely to prepare for your approval the accounts of HEALTH FUSION CLINIC LIMITED and state those matters that we have agreed to state to the Board of Directors of HEALTH FUSION CLINIC LIMITED, as a body, in this report.To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than HEALTH FUSION CLINIC LIMITED and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that HEALTH FUSION CLINIC LIMITED has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit or loss of HEALTH FUSION CLINIC LIMITED.You consider that HEALTH FUSION CLINIC LIMITED is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit of the accounts of HEALTH FUSION CLINIC LIMITED. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the financial statements 31 January 2026.



....................................................
Julius and Julius and Associates LLP
70 Clapton Square
London
E5 8HW
31 October 2026
3
 
 
Notes
 
2026
£
  2025
£
Turnover 519,666    390,056 
Cost of sales (171,098)   (163,798)
Gross [profit_loss) 348,568    226,258 
Direct Cost (71,647)   (41,778)
Administrative expenses (256,591)   (181,066)
Operating profit 20,330    3,414 
Profit/(Loss) on ordinary activities before taxation 20,330    3,414 
Tax on profit on ordinary activities (4,456)   (1,242)
Profit/(Loss) for the financial year 15,874    2,172 
 
4
 
 
Notes
 
2026
£
  2025
£
Fixed assets      
Tangible fixed assets 3 7,958    11,079 
7,958    11,079 
Current assets      
Cash at bank and in hand 2,189    9,717 
Creditors: amount falling due within one year 4 (40,735)   (58,564)
Net current assets (38,546)   (48,847)
 
Total assets less current liabilities (30,588)   (37,768)
Creditors: amount falling due after more than one year 5 (5,890)   (13,343)
Net assets (36,478)   (51,111)
 

Capital and reserves
     
Called up share capital 6 100    100 
Profit and loss account (36,578)   (51,211)
Shareholders' funds (36,478)   (51,111)
 


For the year ended 31 January 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the director on 31 October 2026 and were signed by:


-------------------------------
Ilan SLAZENGER,
Director
5
  Equity share capital   Retained Earnings   Total
£ £ £
At 01 February 2024 100  (53,383) (53,283)
Profit/(Loss) for the year 2,172  2,172 
Total comprehensive income for the year -  2,172  2,172 
Total investments by and distributions to owners -  -  - 
At 31 January 2025 100  (51,211) (51,111)
At 01 February 2025 100  (52,452) (52,352)
Profit/(Loss) for the year 15,874  15,874 
Total comprehensive income for the year -  15,874  15,874 
Total investments by and distributions to owners -  -  - 
At 31 January 2026 100  (36,578) (36,478)
6
General Information
HEALTH FUSION CLINIC LIMITED is a private company, limited by shares, registered in England and Wales, registration number 11161549, registration address 70 Clapton Square, London, E5 8HW.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by Section 1A of the standard)
Going concern basis
The directors believe that the company is experiencing good levels of sales growth and profitability, and that it is well placed to manage its business risks successfully. Accordingly, they have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the financial statements.
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Taxation
Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves.
The company’s liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Current and deferred tax assets and liabilities are not discounted
2.

Average number of employees

Average number of employees during the period was 5 (2025 : 5).
3.

Tangible fixed assets

Cost or valuation Fixtures and Fittings   Total
  £   £
At 01 February 2025 31,213    31,213 
Additions -    - 
Disposals -    - 
At 31 January 2026 31,213    31,213 
Depreciation
At 01 February 2025 20,134    20,134 
Charge for year 3,121    3,121 
On disposals -    - 
At 31 January 2026 23,255    23,255 
Net book values
Closing balance as at 31 January 2026 7,958    7,958 
Opening balance as at 01 February 2025 11,079    11,079 


4.

Creditors: amount falling due within one year

2026
£
  2025
£
Trade Creditors 20,314    - 
Corporation Tax 12,097    28,305 
PAYE & Social Security -    1,038 
Accrued Expenses 6,530    6,530 
Other Creditors - THE FINCHLEY CLINIC LONDON (1)   12,257 
VAT Control Account 1,795    10,434 
40,735    58,564 

5.

Creditors: amount falling due after more than one year

2026
£
  2025
£
Bank Loans & Overdrafts 5,890    13,343 
5,890    13,343 

6.

Share Capital

Allotted, called up and fully paid
2026
£
  2025
£
100 Class A shares of £1.00 each 100    100 
100    100 

7